Archives
Risk Factors For Rapid Disease Progression Of ADPKD
About This Event
Risk Factors For Rapid Disease Progression Of ADPKD
In this presentation rapid disease progression of autosomal dominant polycystic kidney disease (ADPKD) will be defined. The risk factors that assist in determining if a patient is at risk of rapid disease progression will be discussed.
Fleming’s Prime Steakhouse & Wine Bar
Woodland Hills, California 91367 United States + Google Map
Rebecca S. Ahdoot, MD, FASN
Director — PKD Partner Clinic at the UCI School of Medicine*
Dr Rebecca S. Ahdoot is a board-certified UCI Health nephrologist and director of the PKD Partner Clinic at UCI. She specializes in the management of acute and chronic kidney disease, hypertension/high blood pressure, kidney stones, electrolyte abnormalities and dialysis. She earned her medical degree at the UCI School of Medicine and completed an internal medicine residency at Kaiser Permanente Los Angeles Medical Center. She completed a joint neurology fellowship with Kaiser Permanente and Cedars-Sinai in Los Angeles. She also completed the UCLA Kennamer/Kaiser Permanente Community Medicine Fellowship program, which focuses on healthcare policy, patient advocacy and primary care. Dr Ahdoot is passionate about community service and outreach. She founded a bi-annual health fair to address the lack of affordable, timely vision and hearing services for low-income patients. She also has participated in volunteer medical missions to Guatemala through HELPS International.
Marla Dallal, PharmD, RPH
Otsuka Pharmaceutical Development & Commercialization, Inc.*
Marla Dallal, PharmD, RPH is a Medical Science Liaison at Otsuka Pharmaceutical Development and Commercialization covering Southern California. She earned her Doctor of Pharmacy degree from the University of Southern California, School of Pharmacy in Los Angeles. While in pharmacy school, Dr Dallal pursued various clinical internships within the acute care and ambulatory care settings at Cedars-Sinai Medical Center and Kaiser Permanente. Prior to joining Otsuka, Dr Dallal held various positions within Medical Affairs at Amgen Inc covering the cardiometabolic and nephrology therapeutic areas. She also served as a preceptor at Amgen Inc, where she instructed pharmacy students on Advanced Pharmacy Practice rotations. She is currently licensed as a pharmacist in the state of California with the National Association Board of Pharmacy.
*Dr Rebecca Ahdoot is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Marla Dallal is an employee of OPDC.
